{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:32:17Z","timestamp":1792733537132,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127342","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T12:28:17Z","timestamp":1749040097000},"page":"127342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials"],"prefix":"10.1016","volume":"61","author":[{"given":"Sima","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malede Mequanent","family":"Sisay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putri Widi","family":"Saraswati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhadi Khogali","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas P.A.","family":"Zuithoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Ahmadizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127342_bb0005","author":"World","year":"2021"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40264-023-01281-9","article-title":"Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose","volume":"46","author":"Raethke","year":"2023","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127342_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic reviews"},{"key":"10.1016\/j.vaccine.2025.127342_bb0025","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.vaccine.2025.127342_bb0030","first-page":"10","article-title":"Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. Cochrane Methods","author":"Eldridge","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1148\/radiol.220814","article-title":"Axillary lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 vaccination: MRI evaluation","volume":"306","author":"Yoshikawa","year":"2023","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127342_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.787","article-title":"Anaphylaxis and allergic reactions to COVID-19 vaccines: A narrative review of characteristics and potential obstacles on achieving herd immunity","volume":"5","author":"Mahdiabadi","year":"2022","journal-title":"Health Science Reports"},{"key":"10.1016\/j.vaccine.2025.127342_bb0045","first-page":"375","article-title":"SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study","author":"Husby","year":"2021","journal-title":"bmj"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0050","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105923","article-title":"Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System","volume":"30","author":"Pawlowski","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127342_bb0060","article-title":"COVID-19 Vaccine-Related Arthritis: A Descriptive Study of Case Reports on a Rare Complication","volume":"14","author":"Dawoud","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.vaccine.2025.127342_bb0065","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijid.2021.04.047","article-title":"Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers","volume":"106","author":"Kadali","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127342_bb0070","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ana.26339","article-title":"Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS","volume":"91","author":"Frontera","year":"2022","journal-title":"Ann Neurol"},{"issue":"34","key":"10.1016\/j.vaccine.2025.127342_bb0075","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2021.36.e245","article-title":"Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination","volume":"36","author":"Hyun","year":"2021","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0080","article-title":"Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review","volume":"10","author":"SeyedAlinaghi","year":"2022","journal-title":"Arch Acad Emerg Med"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000512152","article-title":"COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist","volume":"39","author":"Hunt","year":"2021","journal-title":"Dig Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127342_bb0090","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0095","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127342_bb0100","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial","volume":"22","author":"Oosting","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Si2","key":"10.1016\/j.vaccine.2025.127342_bb0105","doi-asserted-by":"crossref","first-page":"Si169","DOI":"10.1093\/rheumatology\/keab886","article-title":"SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy","volume":"61","author":"Sampaio-Barros","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0110","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/rheumatology\/keab773","article-title":"Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2","volume":"61","author":"Shinjo","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0115","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.vaccine.2021.12.046","article-title":"Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial","volume":"40","author":"Thomas","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0125","article-title":"Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia","volume":"9","author":"Alamer","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0130","doi-asserted-by":"crossref","first-page":"938.e1-.e6","DOI":"10.1016\/j.jtct.2021.07.008","article-title":"Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients","volume":"27","author":"Ali","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0135","article-title":"Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America","volume":"7","author":"Alonso","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0140","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","article-title":"Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"41","author":"Bartels","year":"2021","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0145","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.14309\/ajg.0000000000001342","article-title":"Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease","volume":"116","author":"Botwin","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0150","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001104","article-title":"COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis","volume":"9","author":"Briggs","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127342_bb0155","first-page":"2183","article-title":"COVID-19 vaccines and cancer patients: acceptance, attitudes and safety","volume":"26","author":"Matovina Brko","year":"2021","journal-title":"J BUON"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0160","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00296-021-04917-0","article-title":"Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey","volume":"41","author":"Cherian","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.vaccine.2025.127342_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108258","article-title":"The impact of SARS-CoV-2 vaccination in Dravet syndrome: A UK survey","volume":"124","author":"Clayton","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127342_bb0170","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/ecco-jcc\/jjac010","article-title":"Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey","volume":"16","author":"Ellul","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127342_bb0175","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00296-021-05017-9","article-title":"Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study","volume":"41","author":"Esquivel-Valerio","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.vaccine.2025.127342_bb0180","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.breast.2021.10.012","article-title":"COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective","volume":"60","author":"Forster","year":"2021","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00296-021-05039-3","article-title":"COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study","volume":"42","author":"Fragoulis","year":"2022","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1756-185X.14279","article-title":"Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study","volume":"25","author":"Haslak","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.127342_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103028","article-title":"Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis","volume":"52","author":"Allen-Philbey","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0200","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajog.2021.06.007","article-title":"Adverse effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional study on healthcare workers with detailed self-reported symptoms","volume":"225","author":"Kadali","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"16","key":"10.1016\/j.vaccine.2025.127342_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18168831","article-title":"Induction of SARS-CoV-2-Specific IgG and IgA in Serum and Milk with Different SARS-CoV-2 Vaccines in Breastfeeding Women: A Cross-Sectional Study in Northern Spain","volume":"18","author":"Lechosa-Mu\u00f1iz","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127342_bb0210","article-title":"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity","volume":"9","author":"Liu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127342_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103189","article-title":"Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases","volume":"55","author":"Lotan","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0220","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1111\/ene.15028","article-title":"Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel","volume":"28","author":"Lotan","year":"2021","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127342_bb0225","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/bfm.2021.0079","article-title":"Maternal and Child Symptoms Following COVID-19 Vaccination Among Breastfeeding Mothers","volume":"16","author":"McLaurin-Jiang","year":"2021","journal-title":"Breastfeed Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030641","article-title":"Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease","volume":"11","author":"Orfanoudaki","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127342_bb0235","article-title":"Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study","volume":"9","author":"Rotondo","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001814","article-title":"Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey","volume":"7","author":"Sattui","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.127342_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108860","article-title":"Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey","volume":"232","author":"Shapiro Ben David","year":"2021","journal-title":"Clin Immunol"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127342_bb0250","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127342_bb0255","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.2147\/JIR.S341429","article-title":"A Web-Based Survey on Factors for Unvaccination and Adverse Reactions of SARS-CoV-2 Vaccines in Chinese Patients with Psoriasis","volume":"14","author":"Wang","year":"2021","journal-title":"J Inflamm Res"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0260","article-title":"Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals","volume":"10","author":"Zdanowski","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11111106","article-title":"Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types","volume":"11","author":"Li","year":"2021","journal-title":"J Pers Med"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127342_bb0270","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0275","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AOG.0000000000004713","article-title":"In Vitro Fertilization and Early Pregnancy Outcomes After Coronavirus Disease 2019 (COVID-19) Vaccination","volume":"139","author":"Aharon","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0280","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/07357907.2021.1992420","article-title":"Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy","volume":"40","author":"Ariamanesh","year":"2022","journal-title":"Cancer Investig"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0285","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0290","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2021.08.007","article-title":"COVID-19 vaccination during pregnancy: coverage and safety","volume":"226","author":"Blakeway","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2025.127342_bb0300","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2021.08.035","article-title":"COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy","volume":"157","author":"Cavanna","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0305","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/cid\/ciab989","article-title":"Epidemiology of Acute Myocarditis\/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination","volume":"75","author":"Chua","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/v14020307","article-title":"Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester","volume":"14","author":"Citu","year":"2022","journal-title":"Viruses"},{"issue":"23","key":"10.1016\/j.vaccine.2025.127342_bb0315","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.2021.7563","article-title":"Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women","volume":"325","author":"Collier","year":"2021","journal-title":"Jama"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127342_bb0320","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-21-2439","article-title":"Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution","volume":"27","author":"Di Noia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2025.127342_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120155","article-title":"COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose","volume":"434","author":"Dreyer-Alster","year":"2022","journal-title":"J Neurol Sci"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0330","article-title":"Anti-TNF\u03b1 Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases","volume":"10","author":"Rabinowitz","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127342_bb0335","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.6002\/ect.2021.0402","article-title":"Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients","volume":"19","author":"Erol","year":"2021","journal-title":"Exp Clin Transplant"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0340","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.127342_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.777103","article-title":"COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads","volume":"12","author":"Golan","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0350","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jama.2021.11035","article-title":"Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women","volume":"326","author":"Goldshtein","year":"2021","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127342_bb0355","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamapediatrics.2022.0001","article-title":"Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes","volume":"176","author":"Goldshtein","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0360","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2021.03.023","article-title":"Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study","volume":"225","author":"Gray","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0370","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1186\/s12885-021-09097-5","article-title":"Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma","volume":"21","author":"Greenberg","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0375","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.06.014","article-title":"COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States","volume":"161","author":"Hadi","year":"2021","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127342_bb0380","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1111\/ajt.16766","article-title":"Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients","volume":"21","author":"Hall","year":"2021","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0385","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1093\/rheumatology\/keac103","article-title":"Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications","volume":"61","author":"Heshin-Bekenstein","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0390","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1097\/TP.0000000000003889","article-title":"Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies","volume":"105","author":"Hod","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2025.127342_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103320","article-title":"COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders","volume":"57","author":"Jovicevic","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"10.1016\/j.vaccine.2025.127342_bb0400","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.vaccine.2024.04.032","article-title":"Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents","volume":"42","author":"Lee","year":"2024","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0405","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2665-9913(21)00394-5","article-title":"Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study","volume":"4","author":"Jyssum","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"33","key":"10.1016\/j.vaccine.2025.127342_bb0410","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.2217\/fon-2021-0597","article-title":"Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy","volume":"17","author":"Karacin","year":"2021","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0415","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028561","article-title":"Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study","volume":"101","author":"Kian","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127342_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100272","article-title":"A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1\/PD-L1 inhibitors: a longitudinal cohort study","volume":"6","author":"Lasagna","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127342_bb0425","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0430","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jnci\/djab174","article-title":"Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients","volume":"114","author":"Ligumsky","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.vaccine.2025.127342_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184621","article-title":"Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group","volume":"13","author":"Linardou","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0440","article-title":"Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors","volume":"9","author":"Liontos","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0445","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/08903344211056522","article-title":"Breastfeeding Mother and Child Clinical Outcomes After COVID-19 Vaccination","volume":"38","author":"Low","year":"2022","journal-title":"J Hum Lact"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0450","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003712","article-title":"Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis","volume":"9","author":"Ma","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127342_bb0455","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/annrheumdis-2021-221490","article-title":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry","volume":"81","author":"Machado","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2025.127342_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103679","article-title":"Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients","volume":"73","author":"Massa","year":"2021","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0465","article-title":"The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation","volume":"9","author":"Matkowska-Kocjan","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0470","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0475","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/TP.0000000000004036","article-title":"Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results","volume":"106","author":"Medina-Pestana","year":"2022","journal-title":"Transplantation"},{"issue":"13","key":"10.1016\/j.vaccine.2025.127342_bb0480","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1055\/a-1745-1168","article-title":"Safety-Related Outcomes of Novel mRNA COVID-19 Vaccines in Pregnancy","volume":"39","author":"Nakahara","year":"2022","journal-title":"Am J Perinatol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0485","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0490","article-title":"Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study","volume":"10","author":"Palaia","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0495","doi-asserted-by":"crossref","first-page":"rkab043","DOI":"10.1093\/rap\/rkab043","article-title":"COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics","volume":"5","author":"Peet","year":"2021","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0500","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.healun.2021.04.003","article-title":"BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response","volume":"40","author":"Peled","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.11.022","article-title":"Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects","volume":"149","author":"Pham","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0510","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127342_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11121283","article-title":"COVID-19 Vaccine Does Not Increase the Risk of Disease Flare-Ups among Patients with Autoimmune and Immune-Mediated Diseases","volume":"11","author":"Pinte","year":"2021","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0520","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients","volume":"75","author":"Rabinowich","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2025.127342_bb0525","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2021.06.002","article-title":"The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience","volume":"154","author":"Revon-Riviere","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0530","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/1471-0528.16941","article-title":"Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study","volume":"129","author":"Rottenstreich","year":"2022","journal-title":"Bjog"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0535","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14495","article-title":"SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications","volume":"36","author":"Russo","year":"2022","journal-title":"Clin Transpl"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0540","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0000000000003983","article-title":"The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant","volume":"106","author":"Sanders","year":"2022","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0545","doi-asserted-by":"crossref","first-page":"160","DOI":"10.6004\/jnccn.2021.7113","article-title":"Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine","volume":"20","author":"Shulman","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"14","key":"10.1016\/j.vaccine.2025.127342_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143573","article-title":"COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience","volume":"13","author":"So","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0555","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13075-021-02674-w","article-title":"Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine","volume":"24","author":"Spinelli","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0560","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00262-021-03133-w","article-title":"Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment","volume":"71","author":"Strobel","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0565","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/1759-7714.14281","article-title":"Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study","volume":"13","author":"Tamura","year":"2022","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0570","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.healun.2022.01.005","article-title":"Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age","volume":"41","author":"Tanner","year":"2022","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127342_bb0575","article-title":"Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy","volume":"3","author":"Theiler","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"22","key":"10.1016\/j.vaccine.2025.127342_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225829","article-title":"Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials","volume":"13","author":"Trillo Aliaga","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0585","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13045-021-01205-z","article-title":"Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies","volume":"14","author":"Tsimafeyeu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.vaccine.2025.127342_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102743","article-title":"A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases","volume":"125","author":"Tzioufas","year":"2021","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030694","article-title":"Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome","volume":"11","author":"Valentini","year":"2022","journal-title":"J Clin Med"},{"issue":"41","key":"10.1016\/j.vaccine.2025.127342_bb0600","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1016\/j.vaccine.2021.09.012","article-title":"Prenatal maternal COVID-19 vaccination and pregnancy outcomes","volume":"39","author":"Wainstock","year":"2021","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127342_bb0605","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/ajt.16966","article-title":"Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers","volume":"22","author":"Watcharananan","year":"2022","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0610","article-title":"The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation","volume":"10","author":"Watanabe","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0615","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ibd\/izab302","article-title":"Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID","volume":"28","author":"Weaver","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0620","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2217\/fon-2021-1248","article-title":"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study","volume":"18","author":"Yasin","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.vaccine.2025.127342_bb0625","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.breast.2021.08.017","article-title":"SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4\/6 inhibitors","volume":"60","author":"Zagouri","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.vaccine.2025.127342_bb0630","article-title":"Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions: CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21","author":"Head Zauche","year":"2021","journal-title":"Res Sq"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127342_bb0635","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/RLU.0000000000003648","article-title":"Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET\/CT: A Cohort Study","volume":"46","author":"Bernstine","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"44","key":"10.1016\/j.vaccine.2025.127342_bb0640","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1016\/j.vaccine.2021.09.043","article-title":"Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study","volume":"39","author":"Bleicher","year":"2021","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127342_bb0645","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29295","article-title":"Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase","volume":"68","author":"Mark","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0650","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.21.01891","article-title":"Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study","volume":"40","author":"Naranbhai","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0655","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.healun.2021.08.010","article-title":"Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience","volume":"41","author":"Peled","year":"2022","journal-title":"J Heart Lung Transplant"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127342_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10153355","article-title":"Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience","volume":"10","author":"Skroza","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127342_bb0665","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S2665-9913(21)00327-1","article-title":"Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study","volume":"4","author":"Aikawa","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0670","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/uog.23729","article-title":"Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine","volume":"58","author":"Bookstein Peretz","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2025.127342_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127342_bb0680","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.acra.2021.04.007","article-title":"Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review","volume":"28","author":"Keshavarz","year":"2021","journal-title":"Acad Radiol"},{"key":"10.1016\/j.vaccine.2025.127342_bb0685","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.033","article-title":"Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care","volume":"159","author":"Garreffa","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2025.127342_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108021","article-title":"Administration of COVID-19 vaccines in immunocompromised patients","volume":"99","author":"Negahdaripour","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2025.127342_bb0695","article-title":"The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0700","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/14760584.2023.2204154","article-title":"Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses","volume":"22","author":"Katoto","year":"2023","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127342_bb0705","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40001-024-01639-4","article-title":"Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis","volume":"29","author":"Shabani","year":"2024","journal-title":"Eur J Med Res"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0710","first-page":"1445","article-title":"Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare?","volume":"62","author":"Nakafero","year":"2023","journal-title":"A self-controlled case series analysis Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127342_bb0715","article-title":"COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations","volume":"9","author":"Yan","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127342_bb0720","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/annrheumdis-2021-221736","article-title":"Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines","volume":"81","author":"Fan","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"Suppl A","key":"10.1016\/j.vaccine.2025.127342_bb0725","doi-asserted-by":"crossref","first-page":"A42","DOI":"10.1093\/eurheartjsupp\/suac123","article-title":"The impact of COVID-19 and COVID vaccination on cardiovascular outcomes","volume":"25","author":"Akhtar","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.vaccine.2025.127342_bb0730","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7031e1","article-title":"COVID-19 vaccine safety in adolescents aged 12\u201317 years\u2014United States, December 14, 2020\u2013July 16, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"35","key":"10.1016\/j.vaccine.2025.127342_bb0735","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15585\/mmwr.mm7135a3","article-title":"COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127342_bb0740","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamapediatrics.2022.6243","article-title":"Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis","volume":"177","author":"Watanabe","year":"2023","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2025.127342_bb0745","unstructured":"Tulane University Institute for Clinical Effectiveness and Health Policy, London School of Hygiene and Tropical Medicine, University of Washington. COVID-19 Vaccines for Pregnant Persons: A Living Systematic Review and Meta-Analysis. Published 2025. Accessed March 8, 2025. Available from: https:\/\/safeinpregnancy.org\/living-systematic-review\/."},{"issue":"9","key":"10.1016\/j.vaccine.2025.127342_bb0750","article-title":"Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis","volume":"10","author":"Kang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127342_bb0755","doi-asserted-by":"crossref","first-page":"1144824","DOI":"10.3389\/fphar.2023.1144824","article-title":"COVID-19 vaccination effectiveness and safety in vulnerable populations: a meta-analysis of 33 observational studies","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127342_bb0760","article-title":"COVID-19 Vaccine Safety Monitoring Studies in Low- and Middle-Income Countries (LMICs)-A Systematic Review of Study Designs and Methods","volume":"11","author":"Sisay","year":"2023","journal-title":"Vaccines (Basel)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25006395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25006395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T21:23:01Z","timestamp":1755897781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25006395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":152,"alternative-id":["S0264410X25006395"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127342","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127342"}}